首页> 外国专利> Fibrinolytic potential: a test of pleural fluid to predict outcomes and guide dosing in fibrinolytic therapy

Fibrinolytic potential: a test of pleural fluid to predict outcomes and guide dosing in fibrinolytic therapy

机译:纤溶潜能:一种测试胸水以预测结局并指导纤溶治疗剂量的方法

摘要

An assay that informs precision-based intrapleural fibrinolytic therapy (IPFT) is disclosed. Provided is a simple assay based on measurement of the Fibrinolytic Potential (FP)—total fibrinolytic activity in pleural fluid when plasminogen activator inhibitors (PAIs) are neutralized and endogenous plasminogen (PLG) is activated. The assay is used to determine FP in baseline pleural fluids of patients undergoing IPFT with agents such as tPA or scuPA to determine the dose and dose intervals for the particular patient. Pleural fluids are also collected after IPFT to confirm that intrapleural fibrinolysis is inhibited and endogenous PLG accumulates in the pleural fluid. Inhibition of intrapleural fibrinolysis in combination with its increase after supplementation of pleural fluid with a plasminogen activator indicates whether or not the subject should be treated with more or higher doses of an IPFT drug.
机译:公开了一种基于精确度的胸膜内纤溶治疗(IPFT)的检测方法。提供了一种基于纤维蛋白溶解潜能(FP)的测量的简单测定方法-纤溶酶原激活物抑制剂(PAI)被中和并激活内源性纤溶酶原(PLG)后,胸膜液中的总纤维蛋白溶解活性。该测定法用于确定接受tFT或scuPA等药物进行IPFT的患者的基线胸腔积液中的FP,以确定特定患者的剂量和剂量间隔。 IPFT后也收集胸膜液,以确认胸膜内纤维蛋白溶解受到抑制,内源性PLG积聚在胸膜液中。补充纤维蛋白溶酶原激活物后,抑制胸膜内纤维蛋白溶解及其增加,表明是否应使用更多或更高剂量的IPFT药物治疗受试者。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号